Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas
β Scribed by Roboz, John ;Jacobs, Allan J. ;Holland, James F. ;Deppe, Gunter ;Cohen, Carmel J.
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 368 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Intraperitoneally administered doxorubicin yields high local concentrations that are expected to deliver higher doses to clinically important peritoneal and lymphatic metastatic sites. Two infusions of 20 mg and 30 mg in a patient with residual microscopic intraperitoneal ovarian cancer eradicated her disease. Quantification of serum doxorubicin by HPLC revealed significant levels of the drug and its major metabolite lasting 72 hours. A 50βmg infusion induced complete remission in endometrial carcinoma; the patient died in 6 months without evidence of abdominal tumor. Complications due to subcutaneous infiltration of doxorubicin and possible systemic effects of sustained high levels of the drug need further investigation to enable the full exploitation of this modality.
π SIMILAR VOLUMES
Modern intracavitary brachytherapy carefully combined with megavoltage external beam radiotherapy is responsible for the high cure rates achieved with radiation treatment of invasive cervical cancers. Pelvic disease recurrence is rare after treatment of patients with tumors <5 cm in diameter, and ev
The Nd:YAG laser has been used for tumor volume reduction of recurrent gynecologic malignant tumors after previous radiation therapy. The localization of the tumor did not allow conventional surgical resection or surgery was contraindicated because of severe medical problems. Hemorrhage caused by re
BACKGROUND. The use of either mitotane or chemotherapy in the treatment of advanced adrenocortical carcinoma (ACC) has led to scanty and controversial results. The recent finding that mitotane is able to reverse in vitro multidrug resistance has provided a rational basis for combining this agent wit